Abstract
The molecular pathogenesis of salivary gland acinic cell carcinoma (AciCC) is poorly understood. The secretory Ca-binding phosphoprotein (SCPP) gene cluster at 4q13 encodes structurally related phosphoproteins of which some are specifically expressed at high levels in the salivary glands and constitute major components of saliva. Here we report on recurrent rearrangements [t(4;9)(q13;q31)] in AciCC that translocate active enhancer regions from the SCPP gene cluster to the region upstream of Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3) at 9q31. We show that NR4A3 is specifically upregulated in AciCCs, and that active chromatin regions and gene expression signatures in AciCCs are highly correlated with the NR4A3 transcription factor binding motif. Overexpression of NR4A3 in mouse salivary gland cells increases expression of known NR4A3 target genes and has a stimulatory functional effect on cell proliferation. We conclude that NR4A3 is upregulated through enhancer hijacking and has important oncogenic functions in AciCC.
Introduction
Salivary gland acinic cell carcinoma (AciCC) has long been a molecular mystery. While many other salivary tumors are defined by specific "fusion genes," AciCC lacked a clear genetic driver. This study identifies a recurrent "wiring error" known as enhancer hijacking as the primary driver of AciCC. By translocating high-powered regulatory elements from saliva-producing genes to the NR4A3 transcription factor, the cancer forces the overproduction of NR4A3, which in turn triggers uncontrolled cell proliferation.
Genomic Architecture and Enhancer Hijacking
Using a multi-omic approach including Whole Genome Sequencing (WGS), ChIP-seq, and Hi-C, researchers identified a recurrent translocation, t(4;9)(q13;q31). This rearrangement moves a "super-enhancer" from the SCPP gene cluster—normally responsible for the high-level production of saliva proteins—and places it adjacent to the NR4A3 locus on chromosome 9.
This is a regulatory rearrangement rather than a structural mutation of the protein itself. The NR4A3 protein remains normal but is expressed at pathologically high levels because it is now under the control of enhancers that are "always on" in salivary tissue. This "hijacking" mechanism effectively plugs a high-voltage regulatory power line into the NR4A3 gene.
Validation and Diagnostic Specificity
The translocation was found in 86% of AciCC cases but was completely absent in 75 other types of salivary tumors, highlighting its potential as a powerful diagnostic biomarker. RNA-seq confirmed that NR4A3 was significantly upregulated in 100% of the AciCC cases studied compared to normal tissue.
Functional validation in cell models demonstrated that overexpressing NR4A3 led to a significant increase in cell numbers and a higher percentage of cells in the S-phase of the cell cycle. This oncogenic switch upregulates downstream targets like CCND1 (Cyclin D1), pushing cells to divide faster. Clinical application is further supported by immunohistochemistry, where 97% of AciCC cases showed strong nuclear staining for the NR4A3 protein.
Conclusion and Future Directions
The discovery of enhancer hijacking as the driver of AciCC provides a clear path for clinical pathologists to identify these tumors. However, therapeutic targeting remains a challenge as NR4A3 is an "orphan" nuclear receptor with unknown natural activating molecules. Future research must focus on finding ways to inhibit its activity or disrupt its interaction with the hijacked enhancers to provide new treatment options for patients.
Summary updated